FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,385,771 | -53.3% | 137,341 | +3.6% | 0.00% | -60.0% |
| Q3 2022 | $2,970,000 | +87.6% | 132,552 | +107.5% | 0.01% | +150.0% |
| Q2 2022 | $1,583,000 | -36.8% | 63,879 | +1.6% | 0.00% | -33.3% |
| Q1 2022 | $2,506,000 | -9.6% | 62,881 | +32.7% | 0.00% | -25.0% |
| Q4 2021 | $2,773,000 | +44.2% | 47,388 | +46.1% | 0.00% | +33.3% |
| Q3 2021 | $1,923,000 | -62.6% | 32,440 | -45.2% | 0.00% | -50.0% |
| Q2 2021 | $5,141,000 | +38.5% | 59,234 | +31.6% | 0.01% | +20.0% |
| Q1 2021 | $3,711,000 | -73.8% | 45,008 | -71.1% | 0.01% | -50.0% |
| Q4 2020 | $14,176,000 | +323.4% | 155,902 | +77.3% | 0.01% | +100.0% |
| Q3 2020 | $3,348,000 | +21.4% | 87,908 | +9.4% | 0.01% | 0.0% |
| Q2 2020 | $2,758,000 | +19.6% | 80,389 | -13.6% | 0.01% | 0.0% |
| Q1 2020 | $2,306,000 | +27.4% | 93,003 | +0.5% | 0.01% | +66.7% |
| Q4 2019 | $1,810,000 | – | 92,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |